跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 12,711 条关于
“Yujiro S. Hata”
全部
12,711
临床试验
4,916
药物
1,614
机构
261
资讯
5,920
3个月前
IDEAYA Biosciences Elevates CEO Yujiro S. Hata to Chairman as Precision Oncology Pipeline Advances Toward Commercialization
去年
IDEAYA Advances Oncology Pipeline with Novel Inhibitors and Gilead Collaboration
去年
IDEAYA's Darovasertib Shows Promise in Neoadjuvant Uveal Melanoma Phase 2 Trial
去年
IDEAYA Nominates IDE034, a First-in-Class B7H3/PTK7 Bispecific ADC, as Development Candidate
去年
IDEAYA Biosciences' Werner Helicase Inhibitor IDE275 Cleared for Phase 1 Trial in MSI-High Solid Tumors
去年
IDEAYA Biosciences Licenses DLL3-Targeting ADC from Hengrui Pharma in $1B Deal
9个月前
IDEAYA Biosciences Receives FDA Clearance for First-in-Class Bispecific ADC IDE034 Targeting Multiple Solid Tumors
去年
IDEAYA Biosciences Reports Strong Pipeline Progress and $1.1B Cash Position for 2024
去年
IDEAYA Nominates IDE034, a First-in-Class B7H3/PTK7 Bispecific ADC, as Development Candidate
9个月前
IDEAYA Biosciences Completes Enrollment in Pivotal Trial for Darovasertib Combination in Metastatic Uveal Melanoma
第 1 页,共 592 页
上一页
下一页